Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. GLP-1 is an endogenous incretin hormone secreted by intestinal L-cells in response to food intake, where it stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals hypothalamic satiety centers. Semaglutide mimics and substantially amplifies these effects through its engineered GLP-1 receptor binding. The compound is available in two formulations: Ozempic (0.5–2 mg weekly injection for type 2 diabetes, FDA approved 2017) and Wegovy (2.4 mg weekly injection for obesity, FDA approved 2021). An oral form (Rybelsus) is approved for type 2 diabetes but at much lower effective doses. The SUSTAIN and STEP clinical trial programs generated the landmark data establishing semaglutide as the most effective anti-obesity pharmacotherapy ever demonstrated in randomized controlled trials. The STEP 1 trial (N=1961) showed 14.9% mean body weight reduction at 68 weeks with 2.4 mg/week versus 2.4% placebo — results that redefined expectations for pharmacological obesity treatment.

Body weight reduction of 15–20% from baseline over 68 weeks is the headline clinical result from the STEP trials. This magnitude of weight loss was previously only achievable with bariatric surgery and represents a paradigm shift in obesity pharmacotherapy. In individual patients, losses of 20–25% or more are not uncommon. Cardiovascular risk reduction is established by the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight or obese adults with established cardiovascular disease. This makes semaglutide uniquely valuable beyond simple weight reduction. Blood sugar control in type 2 diabetes is the original approved indication. Semaglutide significantly reduces HbA1c and is one of the most effective glucose-lowering agents available, with the additional benefit of weight reduction (most diabetes medications cause weight gain). Psychological appetite reduction — a reduction not just in food intake but in the psychological preoccupation with food ("food noise") — is one of the most consistently patient-reported experiences. Many users describe Ozempic as eliminating the constant mental focus on food that characterizes obesity, a distinction from simple caloric restriction.

Gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — are the most common reason for discontinuation, affecting 30–50% of users to some degree. The nausea is most pronounced during dose escalation and typically improves as the titration schedule progresses. Starting at 0.25 mg/week and escalating slowly is essential for GI tolerability. Muscle mass loss concurrent with fat loss is a significant concern, particularly without resistance training. Studies show that while total fat mass declines substantially, lean mass also decreases in a portion that tracks with the overall weight loss. This risks "skinny fat" outcomes — reduced scale weight without improved body composition. Resistance training during semaglutide treatment is strongly recommended. Weight regain after stopping is rapid and nearly complete without permanent behavioral change. Studies show that 2–3 years after stopping, most weight returns. This effectively makes semaglutide a chronic medication rather than a time-limited treatment. Pancreatitis is a reported adverse event requiring discontinuation. Risk is elevated in those with personal or family history of pancreatitis. Thyroid C-cell tumors were observed in rodents and carry an FDA black box warning, though this rodent-specific risk has not been demonstrated in humans. Gallbladder disease risk is elevated with rapid weight loss on any intervention including semaglutide.

Titration schedule: Start at 0.25 mg/week × 4 weeks → 0.5 mg/week × 4 weeks → 1 mg/week × 4 weeks → 1.7 mg/week × 4 weeks → 2.4 mg/week (maintenance for obesity). The slow titration is essential for GI tolerability. Diabetes dosing (Ozempic): 0.5–2 mg/week, titrated based on glucose response. Compounded semaglutide: During shortage periods, compounding pharmacies produced semaglutide at lower cost. FDA has issued guidance on compounded semaglutide quality and the FDA shortage designation. As branded supply has improved, compounding has become more legally restricted. Protein intake: During semaglutide treatment, protein intake of 1.2–1.6 g/kg body weight (or higher) is strongly recommended to minimize lean mass loss given the appetite suppression may make adequate protein intake feel difficult.

United States: Ozempic (type 2 diabetes) and Wegovy (obesity) are FDA approved and available with a prescription. Ozempic is frequently prescribed off-label for obesity in individuals without diabetes. Coverage depends on insurance plan — Wegovy is increasingly covered for obesity; Ozempic coverage for off-label weight loss varies. Compounded semaglutide: During the FDA shortage period, compounding pharmacies legally produced semaglutide. As FDA shortage designation has been lifted (and potentially re-instated depending on timing), the legal status of compounded semaglutide fluctuates. Patients should verify current regulations. WADA: Not on the WADA prohibited list. It is not considered a performance-enhancing drug in the athletic context.

Semaglutide + resistance training: The most evidence-supported "stack" — resistance training during semaglutide treatment preserves lean mass while amplifying fat loss. This is not optional if body composition (rather than just scale weight) is the goal. Semaglutide + protein supplementation: High protein intake (whey protein, casein) during treatment addresses the lean mass risk and the practical difficulty of meeting protein targets when appetite is significantly suppressed. Semaglutide + tirzepatide (if transitioning): Some patients transition from semaglutide to tirzepatide (dual GLP-1/GIP agonist) for enhanced efficacy. These should not be combined; they are alternatives.

Semaglutide — Common Questions